M.D., FESC, FACC, FEACVI
Physician, Cardiologist | Trialist | Innovator | Translational Researcher |
Heart Health Advocate and Volunteer | Messenger
Pioneer of Cardiovascular Nanomedicine
Clinical Cardiology: Non-Invasive, Interventional, Acute and Intensive Care |
Imaging (MSCT/ CCTA, CMR, MPI, PET, TTE, QCA, IVUS, OCT, NIRS) |
Translational Cardiology: Arterial Remodeling/ Atherosclerosis | Biomedical Engineering, Coronary Devices |
Preventive Cardiology and Genetics | Regenerative Medicine and Longevity | Nanomedicine |
Sex- and Gender-Based Medicine | Public Health Management and Advocacy |
Philosophy of Science: Consciousness, Immortality, Singularitarianism, Transhumanism |
Civilizational Anti-Russian Sentiment
Scio quia omnia potes, et nulla te latet cogitatio, Iob 42:2
Potestas et terror apud eum est, qui facit concordiam in sublimibus suis, Iob 25:2
Quia hæc dicit Excelsus, et Sublimis, habitans æternitatem, et sanctum nomen ejus, in excelso et in sancto habitans, et cum contrito et humili spiritu : ut vivificet spiritum humilium, et vivificet cor contritorum, Isaias 57:15
Ego dixi : Dii estis, et filii Excelsi omnes, Psalmi 82:6
Dr. J. A. D. Kharlamov has 25 years of clinical experience in cardiology (since 1996; a Consultant Physician since 2007, a Board-Certified Cardiologist since 2010), 20 years of translational research in nanomedicine and biomedical engineering (since 2001), and about 14 years of the bench-to-bedside studies in interventional cardiology (a leader of the research group since 2007) including academic research in imaging, vascular biology, and pathology, RTD of cardiovascular imaging software (artificial intelligence/ machine learning), medical devices (bioresorbable scaffolds and stents, nanomedicine). He has moved to Russia in babyhood having American, Dutch and British roots, and has received his M.D. (Doctor of Medicine) cum laude in 2005 from Ural State Medical University (Yekaterinburg, Russia). After finishing his internship in internal medicine in 2007 at the Ural Institute of Cardiology (Yekaterinburg, Russia) he started as a physician and translational researcher (a team leader as an Assistant Professor) in the field of interventional cardiology and nanobiotechnologies. The main research direction was an RTD of the multifunctional nanoparticles for theranostics of atherosclerosis. He has passed his C.Sc.-doctoral/ graduate degree course in cardiology (A.B.D.) at the Ural State Medical University in 2008-2011. Since 2007-2009 he has been working as a research fellow in some institutions in the Netherlands (UMC St Radboud, Nijmegen; UMCG, Groningen; Erasmus MC, Rotterdam). He is an author of more than 60 articles and grant proposals for the European Commission and has received for his research work some national and international awards. Since Dec 2018 he is a FESC, and Jan 2019 - a FACC, Jan 2020 - a FEACVI.
h-index = 9. The publication profile is available in ResearchGate, PubMed (akharlamov@orcid), ORCiD (0000-0003-4631-1261), ResearcherID (I-3692-2015), Russian Science Index (7738-9429), and Scopus (56721449700). The editorial/ reviewer profile (Local editorial board member in EuroIntervention in 2011-2013, member of the International Editorial Board in European Heart Journal in 2013-2015, consulting editor in both Cardiovascular Diagnosis and Therapy in 2013-2017, and International Journal of Nanomedicine in 2013-2019), member of the Editorial Board in World Journal of Cardiology (since 2018) and BMC: Cardiovascular Disorders (since 2020) is available in Publons (publons.com/a/1136995/).
European Society of Cardiology - ESC (since 2006; FESC since 2018; FEACVI since 2020), American College of Cardiology - ACC (since 2009; FACC since 2019), American Heart Association - AHA (since 2009), International Society for Stem Cell Research - ISSCR (since 2009), International Society of Nephrology - ISN (since 2009), European Society for Nanomedicine - ESNM (since 2011), The Society for Cardiovascular Angiography and Interventions - SCAI (since 2017), World Sleep Society - WSS (since 2018), The British Society for Nanomedicine - BSN (since 2018), Royal College of Physicians of London - RCP (since 2019), International Society for Cardiovascular Translational Research - ISCTR (since 2019), American Association for the Advancement of Science - AAAS (since 2019), Society of Cardiovascular Computed Tomography - SCCT (since 2019).
De Haar Research Task Force (DHRF, DHRF Pro)
Registered with CoC/ KvK: 75124408
VAT/ BTW: NL002515719B51
The structure of the DHRF includes three labs:
1) Translational Research Lab for Biomedical Engineering and Cardiovascular Nanomedicine (DHRF Cramer Lab) with a focus on translational research and RTD in biomedical engineering (including the artificial womb), nanomedicine, medical devices (multifunctional bioresorbable scaffolds), and regression of atherosclerosis
2) Advanced Cardiovascular Imaging CoreLab (DHRF Da Vinci Lab) is a CoreLab with the expert analysis of both invasive and non-invasive (interventional/ intravascular) techniques in cardiology including the development of the artificial intelligence-based imaging software
3) Trialist Lab (DHRF Van Buren Lab) is essentially an assistant and management research service to the clinical trials in general and interventional cardiology
Please, Support our Task Force and Research Initiative!
All together we can revolutionize cardiology and save millions of lives!
Mapping Twitter followers
Social and Scientific Networking
Analytics of Followers
GET IN ToUCH!
VISITORS STRICTLY BY APPOINTMENT ONLY 24/7
Dr Alexander Kharlamov
T.a.v. Unit 303-G9950